The Role of PRMT5 in Immuno-Oncology
Genes · 09.03.2023 · 14 (3) · 678
DOI: 10.3390/genes14030678 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 09.03.2023. Verfasst von Yoshinori Abe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo 113-8602, Japan. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Immune checkpoint inhibitor (ICI) therapy has caused a paradigm shift in cancer therapeutic strategy. However, this therapy only benefits a subset of patients. The difference in responses to ICIs is believed to be dependent on cancer type and its tumor microenvironment (TME). The TME is favorable for cancer progression and metastasis and can also help cancer cells to evade immune attacks. To improve the response to ICIs, it is crucial to understand the mechanism of how the TME is maintained. Protein arginine methyltransferase 5 (PRMT5) di-methylates arginine residues in its substrates and has essential roles in the epigenetic regulation of gene expression, signal transduction, and the fidelity of mRNA splicing. Through these functions, PRMT5 can support cancer cell immune evasion. PRMT5 is necessary for regulatory T cell (Treg) functions and promotes cancer stemness and the epithelial–mesenchymal transition. Specific factors in the TME can help recruit Tregs, tumor-associated macrophages, and myeloid-derived suppressor cells into tumors. In addition, PRMT5 suppresses antigen presentation and the production of interferon and chemokines, which are necessary to recruit T cells into tumors. Overall, PRMT5 supports an immunosuppressive TME. Therefore, PRMT5 inhibition would help recover the immune cycle and enable the immune system-mediated elimination of cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-Ku, Tokyo 113-8602, Japan.
ORCID-Profile: Yoshinori Abe
Förderung
- JSPS KAKENHI
Zitieren
APA
Abe, Y., Sano, T., & Tanaka, N. (2023). The Role of PRMT5 in Immuno-Oncology. Genes, 14(3), 678. https://doi.org/10.3390/genes14030678
Vancouver
Abe Y, Sano T, Tanaka N. The Role of PRMT5 in Immuno-Oncology. Genes. 2023;14(3):678. doi:10.3390/genes14030678
BibTeX
@article{Abe2023,
author = {Abe, Yoshinori and Sano, Takumi and Tanaka, Nobuyuki},
title = {The Role of PRMT5 in Immuno-Oncology},
journal = {Genes},
year = {2023},
volume = {14},
number = {3},
pages = {678},
doi = {10.3390/genes14030678}
}
EUVIMED